News Biofrontera mulls US IPO to fund skin cancer drug German biotech Biofrontera is considering a US stock market listing to fund development and marketing of a skin cancer drug.
News FDA advisers reject J&J rheumatoid arthritis drug Expert panel concerned about safety of sirukumab.
News AbbVie, Gilead target sick hepatitis C patients in EU Competing hepatitis C combination drugs from AbbVie and Gilead are now approved in the EU, as the companies aim to treat patients who cannot be cured with established regimens.
News Deadline looms for EMA host city bids Europe's medicines regulator will move from London after Brexit
News Relief for AZ as Truqap hits the spot in prostate cancer After a disappointing result with Truqap in triple-negative breast cancer, AstraZeneca chalks up a win in prostate cancer
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
